No Cover Image

Journal article 566 views

In VitroBiochemical Study of CYP51-Mediated Azole Resistance in Aspergillus fumigatus / Andrew G. S. Warrilow, Josie Parker, Claire Price, W. David Nes, Steven Kelly, Diane Kelly

Antimicrobial Agents and Chemotherapy, Volume: 59, Issue: 12, Pages: 7771 - 7778

Swansea University Authors: Josie Parker, Claire Price, Steven Kelly, Diane Kelly

Full text not available from this repository: check for access using links below.

Check full text

DOI (Published version): 10.1128/AAC.01806-15

Abstract

New classes of azole-based drugs are required to combat the increasing resistance to existing triazole therapeutics. In this study, a CYP51 reconstitution assay is described consisting of eburicol, purified recombinant Aspergillus fumigatus CPR1 (AfCPR1), and Escherichia coli membrane suspensions co...

Full description

Published in: Antimicrobial Agents and Chemotherapy
ISSN: 0066-4804 1098-6596
Published: 2015
Online Access: Check full text

URI: https://cronfa.swan.ac.uk/Record/cronfa23614
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract: New classes of azole-based drugs are required to combat the increasing resistance to existing triazole therapeutics. In this study, a CYP51 reconstitution assay is described consisting of eburicol, purified recombinant Aspergillus fumigatus CPR1 (AfCPR1), and Escherichia coli membrane suspensions containing recombinant A. fumigatus CYP51 proteins, allowing in vitro screening of azole antifungals. Our AfCPR1/Af51 assay system demonstrated the biochemical basis for the increased azole resistance of A. fumigatus strains harboring G54W, L98H, and M220K Af51A point mutations.
Keywords: antifungal; Aspergillus fumigatus; CYP 51; CPR; POINT MUTATIONS
College: Swansea University Medical School
Issue: 12
Start Page: 7771
End Page: 7778